Immutep (IMM) Shares Soar 101% Following FDA Orphan Drug Status for Cancer Therapy

Key Takeaways

• Shares of Immutep skyrocketed more than 101% following FDA Orphan Drug Designation approval for eftilagimod alfa (efti).
• The designation applies to soft tissue sarcoma treatment, a rare form of cancer impacting under 200,000 Americans.
• Advantages include market exclusivity for seven years, regulatory assistance, tax incentives, and fee waivers.
• Support for the FDA’s approval stems from Phase II EFTISARC-NEO clinical trial results, achieving its primary goal in 38 participants.
• This development comes after the recent termination of the TACTI-004 Phase III study, projected to push the company’s financial runway past Q2 2027.

The Australian biotechnology firm Immutep experienced a remarkable stock surge on Wednesday following the U.S. Food and Drug Administration’s Orphan Drug Designation award for eftilagimod alfa, the company’s flagship cancer therapeutic.

Immutep Limited, IMMP

Shares of the ASX-traded pharmaceutical company surged 101.3% to reach A$0.079 during Wednesday’s trading session.

The regulatory designation encompasses efti’s application in treating soft tissue sarcoma (STS), an uncommon malignancy representing a significant unmet therapeutic need across the United States.

Receiving ODD provides multiple strategic advantages: expert regulatory consultation, possible tax relief, exemptions from certain fees, and crucially, seven years of exclusive marketing rights upon final approval.

The agency’s determination drew upon findings from the Phase II EFTISARC-NEO clinical investigation. This research evaluated efti when combined with radiotherapy and Merck’s KEYTRUDA (pembrolizumab) in individuals with operable soft tissue sarcoma prior to surgical intervention.

Among 38 evaluable participants, the study successfully achieved its primary objective. Researchers documented a median tumour hyalinization/fibrosis rate of 51.5%, significantly exceeding the predetermined threshold of 35% and far surpassing the historical average of approximately 15% observed with radiotherapy treatment alone.

Findings demonstrated consistency across various sarcoma subcategories. The treatment’s safety characteristics were characterized as promising, with zero instances of surgical delays documented.

TACTI-004 Trial Termination

This encouraging regulatory milestone follows Immutep’s early March decision to discontinue its TACTI-004 Phase III clinical trial. That investigation was evaluating efti for first-line non-small cell lung cancer treatment.

An Independent Data Monitoring Committee advised trial cessation based on futility determinations. The organization is currently conducting an organized wind-down of TACTI-004.

Immutep indicated that terminating the trial should significantly extend its financial resources beyond the previously anticipated Q2 2027 timeframe.

Development Portfolio and Financial Position

In addition to STS and lung cancer applications, Immutep operates five LAG-3 development programs. Among these initiatives, IMP761 is presently undergoing Phase I evaluation for autoimmune condition treatments.

The organization reported a net deficit of A$61.4 million for fiscal year 2025, representing an increase from the A$42.7 million loss recorded in 2024.

As a pre-revenue biotechnology enterprise, Immutep continues requiring supplementary capital to support ongoing research and development operations.

The company maintains strategic collaborations with leading pharmaceutical corporations, including Merck (MSD), to facilitate pipeline advancement.

The EFTISARC-NEO clinical trial results, which provided direct evidence supporting Wednesday’s FDA designation, incorporated translational research findings aligned with efti’s biological mechanism — immune system activation through LAG-3 pathways.

The post Immutep (IMM) Shares Soar 101% Following FDA Orphan Drug Status for Cancer Therapy appeared first on Blockonomi.